Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complementary and alternative medicine for diabetes 2014.
Yang WC, Chang CL, Li CR, Nammi S, Cho WC. Yang WC, et al. Among authors: chang cl. Evid Based Complement Alternat Med. 2015;2015:685248. doi: 10.1155/2015/685248. Epub 2015 Mar 26. Evid Based Complement Alternat Med. 2015. PMID: 25883672 Free PMC article. No abstract available.
Catenarin Prevents Type 1 Diabetes in Nonobese Diabetic Mice via Inhibition of Leukocyte Migration Involving the MEK6/p38 and MEK7/JNK Pathways.
Shen MY, Lin YP, Yang BC, Jang YS, Chiang CK, Mettling C, Chen ZW, Sheu JR, Chang CL, Lin YL, Yang WC. Shen MY, et al. Among authors: chang cl. Evid Based Complement Alternat Med. 2012;2012:982396. doi: 10.1155/2012/982396. Epub 2012 Feb 13. Evid Based Complement Alternat Med. 2012. PMID: 22454693 Free PMC article.
Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet.
Hsieh YY, Su YL, Kuan FC, Chen SG, Chang CL, Shao YY, Tsai CW, Liang YH. Hsieh YY, et al. Among authors: chang cl. Am J Cancer Res. 2024 Dec 15;14(12):5909-5920. doi: 10.62347/MUCQ4129. eCollection 2024. Am J Cancer Res. 2024. PMID: 39803663 Free PMC article.
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Maćkowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS. Oaknin A, et al. Among authors: chang cl. Eur J Cancer. 2025 Jan 10;216:115146. doi: 10.1016/j.ejca.2024.115146. Online ahead of print. Eur J Cancer. 2025. PMID: 39798514
1,231 results